In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 clinical study titled ‘MagnetisMM-32’ ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled A RANDOMIZED, 2-ARM, ...

Senator Ron Johnson Exposes Government Cover-Up on COVID Vaccine Risks In a scathing Senate testimony, Senator Ron Johnson (R-WI) pulled back the curtain on what many are now call ...

Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and ...

As July draws to a close, it's time to take a look at what's in store in the health and wellness space over the upcoming weeks.August, the last month of summer, includes several ...

New research is calling for further study on a possible link between COVID-19 jabs and long-term vision issues.

What's needed is a course correction. Congress and the Trump administration can start by passing the EPIC Act. They should ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Here are four high-yield blue-chip pharmaceutical stocks positioned to outperform and offer huge total return potential.

First-line treatment with the monoclonal antibody is associated with more patients achieving robust clinical response at 3 months vs standard of care, but by 6 months no advantage remained.